Back to Clinical Trials Overview

Your search for "Lung" returned 14 results:


A randomized, double blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of dupilumab in patients with persistent asthma
Principal Investigator(s): Linda Rogers

A Randomized, Open-Label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections Caused by Mycobacterium avium complex (MAC) That are Refractory to Treatment
Principal Investigator(s): Louis DePalo

A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 compared to PT005 on COPD Exacerbations over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Principal Investigator(s): E. Neil Schachter

A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD)
Principal Investigator(s): Maria Padilla

WTC CHEST (Pulmonary Abnormalities, Diastolic Dysfunction, and World Trade Center Exposure: Implications for Diagnosis and Treatment)
Principal Investigator(s): Mary Ann McLaughlin, MD MPH

A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Principal Investigator(s): Maria Padilla

Open–label extension study to evaluate the long-term safety and tolerability of dupilumab in patients with asthma who participated in a previous dupilumab asthma clinical study
Principal Investigator(s): Linda Rogers

American Legacy Smoking Cessation Study
Principal Investigator(s): Claudia I. Henschke

Determinants fo Undertreatment Amoung Patients with Chronic Obstructive Pulmonary Disease
Principal Investigator(s): Wisnivesky, Juan P

A Phase II Randomized Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients with Idiopathic Pulmonary Fibrosis
Principal Investigator(s): Maria Padilla

Pulmonary Diseases from Secondhand Smoke
Principal Investigator(s): Claudia I. Henschke

Clinic-based vs. home-based support to improve outcomes for older asthmatics
Principal Investigator(s): Alex Federman

Asthma Mobile Health App study
Principal Investigator(s): Yvonne Chan

A Multi-Centre Open-Label Study of Mepolizumab in a Subset of Subjects with a History of Life Threatening/Seriously Debilitating Asthma Who Participated in the MEA115661 Trial
Principal Investigator(s): Gwen Skloot